Cargando…

TCR-Engineered Lymphocytes Targeting NY-ESO-1: In Vitro Assessment of Cytotoxicity against Tumors

Adoptive T-cell therapies tailored for the treatment of solid tumors encounter intricate challenges, necessitating the meticulous selection of specific target antigens and the engineering of highly specific T-cell receptors (TCRs). This study delves into the cytotoxicity and functional characteristi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alsalloum, Alaa, Alrhmoun, Saleh, Shevchenko, Julia, Fisher, Marina, Philippova, Julia, Perik-Zavodskii, Roman, Perik-Zavodskaia, Olga, Lopatnikova, Julia, Kurilin, Vasily, Volynets, Marina, Akahori, Yasushi, Shiku, Hiroshi, Silkov, Alexander, Sennikov, Sergey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604587/ https://www.ncbi.nlm.nih.gov/pubmed/37893178 http://dx.doi.org/10.3390/biomedicines11102805

Ejemplares similares

Exploring TCR-like CAR-Engineered Lymphocyte Cytotoxicity against MAGE-A4
por: Alsalloum, Alaa, et al.
Publicado: (2023)

Murine Bone Marrow Erythroid Cells Have Two Branches of Differentiation Defined by the Presence of CD45 and a Different Immune Transcriptome Than Fetal Liver Erythroid Cells
por: Perik-Zavodskaia, Olga, et al.
Publicado: (2023)

Murine Placental Erythroid Cells Are Mainly Represented by CD45(+) Immunosuppressive Erythroid Cells and Secrete CXCL1, CCL2, CCL3 and CCL4 Chemokines
por: Nazarov, Kirill, et al.
Publicado: (2023)

Immune Transcriptome Study of Human Nucleated Erythroid Cells from Different Tissues by Single-Cell RNA-Sequencing
por: Perik-Zavodskii, Roman, et al.
Publicado: (2022)

TNFα Causes a Shift in Gene Expression of TNFRSF1A and TNFRSF1B Isoforms
por: Perik-Zavodskaia, Olga, et al.
Publicado: (2023)

Human Fetal Liver Parenchyma CD71+ Cells Have AIRE and Tissue-Specific Antigen Gene Expression
por: Perik-Zavodskii, Roman, et al.
Publicado: (2022)

Immunoregulatory properties of erythroid nucleated cells induced from CD34+ progenitors from bone marrow
por: Shevchenko, Julia A., et al.
Publicado: (2023)

Immune Transcriptome and Secretome Differ between Human CD71(+) Erythroid Cells from Adult Bone Marrow and Fetal Liver Parenchyma
por: Perik-Zavodskii, Roman, et al.
Publicado: (2022)

Cytotoxic Activity and Memory T Cell Subset Distribution of in vitro-Stimulated CD8(+) T Cells Specific for HER2/neu Epitopes
por: Kuznetsova, Maria, et al.
Publicado: (2019)

Pushing forward in sarcoma with a new TCR targeting NY-ESO-1
por: Al-Marayaty, Rusul, et al.
Publicado: (2023)

The Melanoma-Associated Antigen Family A (MAGE-A): A Promising Target for Cancer Immunotherapy?
por: Alsalloum, Alaa, et al.
Publicado: (2023)

Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma
por: Gyurdieva, Alexandra, et al.
Publicado: (2022)

Dendritic Cells Transfected with MHC Antigenic Determinants of CBA Mice Induce Antigen-Specific Tolerance in C57Bl/6 Mice
por: Sennikov, Sergey V., et al.
Publicado: (2020)

NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome
por: Ishihara, Mikiya, et al.
Publicado: (2022)

Deep phenotypic characterization of NY-ESO TCR engineered T cells and tumor in patients with advanced myeloma
por: Davila, Eduardo, et al.
Publicado: (2015)

Polymorphisms in the Tumor Necrosis Factor Receptor Genes Affect the Expression Levels of Membrane-Bound Type I and Type II Receptors
por: Sennikov, Sergey V., et al.
Publicado: (2014)

Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells
por: Gong, Wenjie, et al.
Publicado: (2021)

Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients
por: Kageyama, Shinichi, et al.
Publicado: (2013)

NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma
por: Rapoport, Aaron P., et al.
Publicado: (2015)

The Effects of Immunosuppressive Factors on Primary Dendritic Cells from C57BL/6 and CBA Mice
por: Kurilin, Vasiliy V., et al.
Publicado: (2019)

First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors
por: Ishihara, Mikiya, et al.
Publicado: (2020)

Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101–0103 and Recognized by Cd4(+)T Lymphocytes of Patients with Ny-Eso-1–Expressing Melanoma
por: Jäger, Elke, et al.
Publicado: (2000)

HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma
por: Gong, Wenjie, et al.
Publicado: (2022)

Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors
por: McCormack, Emmet, et al.
Publicado: (2012)

Synergistic Therapeutic Effects of Low Dose Decitabine and NY-ESO-1 Specific TCR-T Cells for the Colorectal Cancer With Microsatellite Stability
por: Yu, Ganjun, et al.
Publicado: (2022)

Reprogramming of IL-12 secretion in the PDCD1 locus improves the anti-tumor activity of NY-ESO-1 TCR-T cells
por: Kim, Segi, et al.
Publicado: (2023)

Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy
por: Liu, Xin, et al.
Publicado: (2022)

Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype
por: Kang, Synat, et al.
Publicado: (2022)

NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
por: Thomas, Remy, et al.
Publicado: (2018)

NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma
por: Liu, Zhenjiang, et al.
Publicado: (2017)

MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours
por: Ishihara, Mikiya, et al.
Publicado: (2020)

TCR Sequencing in Mouse Models of Allorecognition Unveils the Features of Directly and Indirectly Activated Clonotypes
por: Tereshchenko, Valeriy, et al.
Publicado: (2023)

NY-ESO-1 antibody as a novel tumour marker of gastric cancer
por: Fujiwara, S, et al.
Publicado: (2013)

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma
por: Giesen, Eva, et al.
Publicado: (2014)

NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target
por: Lai, Jin-Ping, et al.
Publicado: (2012)

NY-ESO-1 expression in DCIS: A new predictor of good prognosis
por: Coombes, R. Charles, et al.
Publicado: (2017)

Involvement of NY-ESO-1 and MAGE-A4 in the pathogenesis of desmoid tumors
por: Hashimoto, Kazuhiko, et al.
Publicado: (2023)

Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer
por: Karbach, Julia, et al.
Publicado: (2023)

Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141(+) dendritic cells to activate naïve and memory NY-ESO-1-specific CD8(+) T cells
por: Masterman, Kelly-Anne, et al.
Publicado: (2020)

Genetic engineering of T cells with receptors from NY-ESO-1-specific tumor-recognizing CD4+ T cell as a novel approach for adoptive T cell therapy
por: Matsuzaki, Junko, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_beskhrr5i202h76uqnmffn4cns